Citius Oncology Inc (CTOR): Next-Year EPS Estimate 119.23%
As of 2026-06-11, Citius Oncology Inc (CTOR) has a next-year EPS growth estimate of 119.23%.
On 2026-05-20, analyst consensus for CTOR's next-year EPS growth shifted from 343.75% to 119.23% — a negative change of 224.52 percentage points. The revised estimate has been sustained across 17 subsequent trading sessions. Current-year growth is projected at -52.94%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- EPS growth next year
- 119.23%
- EPS growth this year
- -52.94%
- EPS next quarter (est)
- -$0.04
- Last price
- $0.69
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-11 | 119.23% | -52.94% | -$0.04 | $0.69 |
| 2026-06-10 | 119.23% | -52.94% | -$0.04 | $0.69 |
| 2026-06-09 | 119.23% | -52.94% | -$0.04 | $0.72 |
| 2026-06-08 | 119.23% | -52.94% | -$0.04 | $0.80 |
| 2026-06-07 | 119.23% | -52.94% | -$0.04 | $0.78 |
| 2026-06-04 | 119.23% | -52.94% | -$0.04 | $0.80 |
| 2026-06-03 | 119.23% | -52.94% | -$0.04 | $0.78 |
| 2026-06-02 | 119.23% | -52.94% | -$0.04 | $0.78 |
| 2026-06-01 | 119.23% | -52.94% | -$0.04 | $0.79 |
| 2026-05-31 | 119.23% | -52.94% | -$0.04 | $0.80 |
| 2026-05-28 | 119.23% | -52.94% | -$0.04 | $0.81 |
| 2026-05-27 | 119.23% | -52.94% | -$0.04 | $0.89 |
| 2026-05-26 | 119.23% | -52.94% | -$0.04 | $0.86 |
| 2026-05-25 | 119.23% | -52.94% | -$0.04 | $0.84 |
| 2026-05-24 | 119.23% | -52.94% | -$0.04 | $0.84 |
| 2026-05-21 | 119.23% | -52.94% | -$0.04 | $0.83 |
| 2026-05-20 | 119.23% | -52.94% | -$0.04 | $0.83 |
| 2026-05-19 | 343.75% | 52.94% | $0.00 | $0.83 |
| 2026-05-18 | 343.75% | 52.94% | $0.00 | $0.83 |
| 2026-05-17 | 343.75% | 52.94% | $0.00 | $0.96 |
| 2026-05-14 | 343.75% | 52.94% | -$0.01 | $0.98 |
| 2026-05-13 | 343.75% | 52.94% | -$0.01 | $0.98 |
| 2026-05-12 | 343.75% | 52.94% | -$0.01 | $0.90 |
| 2026-05-11 | 343.75% | 52.94% | -$0.01 | $0.90 |
| 2026-05-10 | 343.75% | 52.94% | -$0.01 | $0.91 |
| 2026-05-07 | 343.75% | 52.94% | -$0.01 | $0.90 |
| 2026-05-06 | 343.75% | 52.94% | -$0.01 | $0.91 |
| 2026-05-05 | 343.75% | 52.94% | -$0.01 | $0.96 |
| 2026-05-04 | 343.75% | 52.94% | -$0.01 | $0.92 |
| 2026-05-03 | 343.75% | 52.94% | -$0.01 | $0.94 |
Screen Performance
Aggregate stats across all 1781 tickers our top-EPS-revision screen has flagged over the past 71 days.
- Median return since detection
- +3.8%
- % of tickers in the green
- 58%
- Median return on winners
- +18.5%
- Large revisions captured
- 788
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Citius Oncology Inc's next-year EPS growth estimate?▾
As of 2026-06-11, Citius Oncology Inc (CTOR) has a next-year EPS growth estimate of 119.23%, based on analyst consensus.
When was the latest EPS estimate revision for CTOR?▾
The most recent revision occurred on 2026-05-20, when analysts adjusted the next-year EPS growth estimate from 343.75% to 119.23%.
What sector and industry does Citius Oncology Inc belong to?▾
Citius Oncology Inc operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. CTOR appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Citius Oncology Inc (CTOR) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports